Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

NCT01922375 is registered in ClinicalTrials.gov with Dong-A Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01922375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01922375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Lead sponsor
Dong-A Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
September 30, 2012
Enrollment
411 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lower urinary tract symptoms associated with benign prostatic hyperplasia